The task force's three key recommendations for defining remission in SLE
Key principles for defining remission in SLE
Agreement
1.
▸ Definitions of remission in SLE will be worded as follows: Remission in SLE is a durable state characterized by …………………. (reference to symptoms, signs, routine labs)
▸ Requirement for serology may be added
93% (2 abstained)
2.
▸ For defining remission in SLE, a validated index must be used
▸ Suggested indices are: clinical SLEDAI=0; BILAG 2004 D or E only; clinical ECLAM=0
▸ These must be supplemented by the physician's global assessment being below an appropriate threshold (eg, <0.5 on a 0–3 scale)
98%
3.
▸ A distinction will be made between remission off therapy and remission on therapy
– Remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials
▸ Remission on therapy allows patients to be treated with maintenance antimalarials, stable, low-dose glucocorticoids (eg, prednisone ≤5 mg/day), maintenance immunosuppressives and/or stable (maintenance) biologics
100% (3 abstained)
ECLAM, European consensus lupus outcome measure; SLE, systemic lupus erythematosus.